Ascendis

Capital Fund Management S.A. acquired a new position in shares of Ascendis Pharma A/S during the third quarter valued at $2,270,000.

On average, equities research analysts predict that Ascendis Pharma A/S will post -10.64 earnings per share for the current year.

Research analysts forecast that Ascendis Pharma A/S will post -11.03 earnings per share for the current fiscal year.

Campbell & CO Investment Adviser LLC purchased a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $503,000.

Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S ( in a report published on Monday, reports.

Finally, Bessemer Group Inc. lifted its position in Ascendis Pharma A/S by 61.0% during the first quarter.

On average, analysts expect Ascendis Pharma A/S to post $-7 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2021 earnings at ($7.94) EPS.

Tower Research Capital LLC TRC purchased a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $52,000.

Wedbush reaffirmed a “buy” rating and set a $186.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, November 19th.

Wedbush restated a “buy” rating and set a $223.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, June 28th.